Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118444 | 0.96 | TP53 (0.42) | TP53MAPTAGTR1CYP4A11AGTR2 | |
| SCHEMBL5111306 | 0.93 | TP53 (0.39) | TP53MAPTOPRL1SCN9A | |
| SCHEMBL5118191 | 0.93 | TP53 (0.39) | TP53MAPTOPRL1SCN9A | |
| SCHEMBL5126197 | 0.92 | TP53 (0.39) | TP53MAPTSCN9A | |
| SCHEMBL5256018 | 0.92 | RARB (0.39) | TP53MAPTSCN9A | |
| SCHEMBL5113535 | 0.89 | TP53 (0.38) | TP53MAPTOPRL1SCN9A | |
| SCHEMBL5114130 | 0.88 | TP53 (0.45) | TP53MAPT | |
| SCHEMBL5216357 | 0.88 | TP53 (0.41) | TP53MAPT | |
| SCHEMBL5124414 | 0.88 | TP53 (0.39) | TP53MAPTSCN9A | |
| SCHEMBL5117738 | 0.86 | TP53 (0.37) | TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | TP53 482/4885MAPT 3986/4885AGTR1 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.